Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Downey, California Clinical Trials

A listing of Downey, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (11) clinical trials

Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder

The study will enroll approximately 375 subjects randomized 1:1:1 to dose regimens of 180g, 120g BXCL501, or placebo stratified by age < 65 and age 65. Male and female adults with acute agitation associated with bipolar disorder will be enrolled. Eligible subjects (acutely agitated subjects with bipolar disorder, generally hypomanic, ...

Phase

6.3 miles

Learn More »

Safety and Efficacy of ActiGraft Compared to Standard of Care in DFUs

The study is a multi-center, prospective, randomized, controlled, single blinded clinical study consisting of 150 subjects from up to 20 centers. The subjects are randomized to receive 1 of 2 treatments, either with ActiGraft and standard of care (SOC) or with SOC alone. The target ulcers are evaluated weekly by ...

Phase N/A

7.78 miles

Learn More »

Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer

PRIMARY OBJECTIVES: I. To determine the safety, tolerability, maximum tolerated dose (MTD)/recommended phase 2 dose (R2PD) of guadecitabine in combination with nivolumab in patients with refractory CpG island methylator phenotype (CIMP+) metastatic colorectal cancer. (Phase Ib Dose Escalation) II. To assess the overall response rate (ORR) in refractory CIMP+ metastatic ...

Phase

8.65 miles

Learn More »

Noninvasive Spinal Cord Stimulation for Neurogenic and Idiopathic Overactive Bladder

Overactive bladder (OAB) affects 12-30% of the world's population. The accompanying urinary urgency, urinary frequency and incontinence can impair the ability to work, interact in social activities and can result in poor social functioning. Multiple treatment modalities are available for overactive bladder. However, each therapy has drawbacks that limit its ...

Phase N/A

8.65 miles

Learn More »

Betaquik as an Adjunct to Dietary Management of Epilepsy in Adults on the Modified Atkins Diet

The purpose of this pilot study is to measure adherence and quality of life in adults with intractable epilepsy following the Modified Atkins Diet (MAD) with Betaquik, a ready-to-use medium chain triglyceride (MCT) emulsion, as an adjunct to the MAD. The participants dietitian will recommend an appropriate daily intake of ...

Phase N/A

8.65 miles

Learn More »

Fluid Biopsy for the Diagnosis of Lung Cancer

PRIMARY OBJECTIVE: I. To estimate the sensitivity and specificity of the fluid biopsy in establishing a diagnosis of bronchogenic carcinoma. SECONDARY OBJECTIVES: I. To determine the accuracy of determination of the histologic subtype of bronchogenic lung cancer. II. To determine the relative contribution of cell based high definition circulating tumor ...

Phase N/A

8.65 miles

Learn More »

Regorafenib With Cetuximab or Panitumumab for the Treatment of Unresectable Locally Advanced or Metastatic Colorectal Cancer

PRIMARY OBJECTIVE: I. To compare the overall survival between evaluable patients who were randomized to receive regorafenib followed by anti-EGFR monoclonal antibody therapy compared to those that receive anti-EGFR monoclonal antibody followed by regorafenib. SECONDARY OBJECTIVES: I. To compare the first progression free survival (PFS1) of patients between evaluable patients ...

Phase

8.84 miles

Learn More »

SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes

This study compares the effect and safety of 2 dose schedules for semaglutide (study medicine) in people with type 2 diabetes previously treated with a diabetes medicine similar to semaglutide. The study will also evaluate the use of a new pen-injector for semaglutide used to inject medicine under the skin, ...

Phase

9.63 miles

Learn More »

A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants

Treatment will begin on Day 1 and then participants will be followed for 60 days post-last dose for safety. Treatment will be administered until the participant has a successful outcome or for a maximum duration of 84 days (IA) or 180 days (IM), whichever occurs first. Participants will receive a ...

Phase

9.81 miles

Learn More »